Sugi Predict

Sugi Predict / Compounds / SCHEMBL386165

SCHEMBL386165

SCHEMBL386165

COCCOc1ccc(C(=O)OC)cc1

nearest known ligand 0.89

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.89
▸ RAB9A P51151 3/20 0.77
▸ TDP1 Q9NUW8 2/20 0.65
▸ L3MBTL1 Q9Y468 2/20 0.65
▸ CA1 P00915 2/20 0.60
▸ CA2 P00918 2/20 0.60
▸ NPC1 O15118 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ KDM4E B2RXH2 2/20 0.55
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ PLK1 P53350 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ CA12 O43570 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ CA14 Q9ULX7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21063817 0.95 MAPT (0.80) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL14926517 0.95 MAPT (0.80) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL1951546 0.94 MAPT (1.00) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL15693338 0.91 MAPT (0.79) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL1796892 0.91 MAPT (0.79) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL6132720 0.89 MAPT (0.77) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL10295289 0.89 MAPT (0.77) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL6132617 0.89 MAPT (0.77) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL7324122 0.89 MAPT (0.77) MAPTRAB9ATDP1L3MBTL1CA1
SCHEMBL14274445 0.89 MAPT (0.89) MAPTRAB9ATDP1L3MBTL1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118027412-A Photo-alignment material 罗利克技术有限公司 2024-05-14 — — CN disclosed
US-11634544-B2 Photoaligning materials Rolic Technologies AG (CH) 2023-04-25 — — US disclosed
EP-3324977-B1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2022-07-13 — — EP disclosed
US-20210340330-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2021-11-04 — — US disclosed
CN-108912011-B Photoalignment material 罗立克科技股份公司 2021-09-24 — — CN disclosed
CN-108863850-B Biaryl compound and preparation method and application thereof 复旦大学 2021-05-18 — — CN disclosed
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-01-05 — — US disclosed
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-15 — — US disclosed
US-10738242-B2 Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element DIC CORPORATION (JP) 2020-08-11 — — US disclosed
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2020-07-16 — — US disclosed
WO-2013050122-A1 PHOTOALIGNING MATERIALS ROLIC AG (CH) 2013-04-11 — — WO disclosed
WO-2013050121-A1 PHOTOALIGNING MATERIALS ROLIC AG (CH) 2013-04-11 — — WO disclosed
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 — — US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 — — EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 — — US disclosed
US-7485752-B2 Diacylglycerol acyltransferase inhibitors HOFFMAN-LA ROCHE INC. (US) 2009-02-03 — — US disclosed
US-7485752-B2 Diacylglycerol acyltransferase inhibitors HOFFMAN-LA ROCHE INC. (US) 2009-02-03 — — US disclosed
EP-1948617-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 — — EP disclosed
US-7317125-B2 Diacylglycerol acyltransferase inhibitors HOFFMAN-LA ROCHE INC. (US) 2008-01-08 — — US disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 MAPT 2157/4885RAB9A 1384/4885TDP1 3446/4885
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors SERPINB1, FURIN, HIF1AN MAPT 3417/4885RAB9A 704/4885TDP1 4500/4885
US-10738242-B2 Compound, cured product, polymer, photo-alignment film, optically anisotropic body and liquid crystal display element PYM1, ZYX, CRY1 MAPT 2680/4885RAB9A 3193/4885TDP1 3029/4885
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 MAPT 2157/4885RAB9A 1384/4885TDP1 3446/4885
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 MAPT 1859/4885RAB9A 3959/4885TDP1 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.